Alurar rigakafin typhoid
 Alurar rigakafin typhoid | |
|---|---|
essential medicine (en)  da vaccine type (en) | |
 | |
| Bayanai | |
| Ƙaramin ɓangare na |
typhoid-paratyphoid vaccines (en) |
| Vaccine for (en) | Zazzabin Rawaya |
| WordLift URL (en) | http://data.medicalrecords.com/medicalrecords/healthwise/typhoid_vaccines__what_you_need_to_know |
.jpg)
Alurar rigakafin typhoid alluran rigakafi ne da ke hana zazzabin typhoid. Akwai nau'o'i da yawa: maganin typhoid conjugate (TCV), Ty21a (alurar rigakafi mai rai ) da Vi capsular polysaccharide (ViPS) ( alurar riga- kafi).[1] Suna da kusan kashi 30 zuwa 70% masu tasiri a cikin shekaru biyu na farko, ya danganta da takamaiman maganin da ake tambaya. An nuna maganin rigakafin Vi-rEPA yana da amfani ga yara.[2] maganan gaskin gyaran ne ake tayi dimin samun ddamar.[3]
Amfanin likitanci
[gyara sashe | gyara masomin]Ty21a, maganin Vi capsular polysaccharide, da Vi-rEPA suna da tasiri wajen rage zazzaɓin typhoid tare da ƙananan sakamako masu illa. Sabbin alluran rigakafi irin su Vi-TT (PedaTyph) suna jiran [yaushe?] gwaje-gwajen filin don nuna inganci a kan fallasa na halitta. Alurar rigakafi ta baka ta Ty21a tana hana kusan rabin cututtukan taifot a cikin shekaru uku na farko bayan alurar riga kafi.[4] Alurar rigakafin Vi polysaccharide mai allura ya hana kusan kashi biyu bisa uku na cututtukan typhoid a cikin shekara ta farko kuma yana da ingantaccen tasiri na 55% a shekara ta uku. An nuna ingancin waɗannan alluran rigakafin a cikin yara waɗanda suka wuce shekaru biyu kawai. Alurar rigakafin Vi-rEPA, sabon nau'i na haɗin gwiwa na allurar Vi, na iya zama mafi inganci kuma yana hana cutar a yawancin yara 'yan ƙasa da shekaru biyar. A cikin gwaji a cikin yara masu shekaru 2 zuwa 5 a Vietnam, maganin yana da inganci fiye da kashi 90 cikin ɗari a cikin shekara ta farko kuma kariya ta ɗauki akalla shekaru huɗu.[5]
Jadawalin
[gyara sashe | gyara masomin]Dangane da tsarin za a iya ba da shi tun yana ɗan shekara biyu (ViPS), shida (Ty21a), ko wata shida (TCV)[5][6]
Manazarta
[gyara sashe | gyara masomin]- ↑ World Health Organization (2018). "Typhoid vaccines: WHO position paper – March 2018". Weekly Epidemiological Record. 93 (13): 153–172. hdl:10665/272273.
- ↑ https://www.apollohospitals.com/ha/health-library/vaccination-frequently-asked-questions-faqs
- ↑ https://www.apollohospitals.com/ha/health-library/vaccination-frequently-asked-questions-faqs
- ↑ World Health Organization (2019). "Typhoid vaccines: WHO position paper, March 2018 - Recommendations". Vaccine. 37 (2): 214–216. doi:10.1016/j.vaccine.2018.04.022. PMID 29661581. S2CID 4902671.
- ↑ 5.0 5.1 "Summary of the WHO Position Paper on Typhoid vaccines: WHO position paper – March 2018" (PDF). origin.who.int. October 23, 2019. Archived from the original (PDF) on October 23, 2019.
- ↑ World Health Organization (2019). "Typhoid vaccines: WHO position paper, March 2018 - Recommendations". Vaccine. 37 (2): 214–216. doi:10.1016/j.vaccine.2018.04.022. PMID 29661581. S2CID 4902671.